10:58 AM EST, 01/23/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) started a phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis.

Trial is intended to evaluate safety, tolerability, pharmacokinetics and immunogenicity in 40 adults with early proof-of-concept results expected in Q3, the company said Thursday in a statement.

Price: 7.48, Change: -0.02, Percent Change: -0.27